Exhibit 10.18


 





	 



  


May
19, 2014


 


PRIVATE
AND CONFIDENTIAL


 


Stuart
Grant


206
Belle Meade Court


Waxhaw,
NC 28173


 


RE:
Amendment to Employment Contract


 


Dear
Stuart:


 


Further
to our discussions, this letter (the “Letter”), effective as of June 9, 2014 (the “Amendment Effective Date”),
confirms that Patheon Pharmaceutical Services inc. (the “Company”), has agreed to increase your base salary in your
current role of Executive Vice President, Chief Financial Officer, and has further agreed to provide you with the equity grant
described below. Once signed, this Letter will serve as the first amendment to the Employment Agreement between you and the Company
dated January 25, 2011 (the “Employment Agreement”). Any terms used in this Letter that are not defined herein have
the definition ascribed to them in the Employment Agreement.


 


For
purposes of clarity, please be advised that the Company is a subsidiary of DPx Holdings B.V. (“DPx”). DPx the corporate
parent of a group of businesses engaged in the provision of commercial manufacturing and development services (pharmaceuticals
and fine chemicals), related services, and the development, manufacture, distribution and marketing of proprietary products. The
Company serves as the corporate shared services entity for DPx and other members of the DPx Group.


	 	 	 
	 	1.	General Provisions
	 	 	 
	 	 	This Letter, when fully executed, together with the Employment
    Agreement, reflects the entire agreement regarding the terms and conditions of your employment. Unless expressly modified
    by this Letter, the terms and conditions of the Employment Agreement, including without limitation your confidentiality, assignment
    of inventions, non-solicitation and non-competition undertakings, will remain the same.
	 	 	 
	 	2.	Compensation & Benefits


 


	 	a.	Base Salary: In recognition of your
    performance, your annual base salary will be increased to $475,000, subject to standard withholdings and deductions and payable
    in regular installments in accordance with the Company’s normal payroll practices.



 





	 	 	 	 	 


 



    	 



    	 



    

 


	 	b.	Equity Incentive Plan:
	 	 	 
	 	 	(i)          You
    shall be eligible to participate in the JLL/DELTA PATHEON HOLDINGS, L.P. 2014 Equity Incentive Plan (the “MEIP”)
    and shall be eligible to be awarded Membership Units from time to time in accordance with the terms of such MEIP, the Membership
    Unit award agreement, and all related documents (collectively, the MEIP Related Documents”).
	 	 	 
	 	 	(ii)          Subject
to approval of the Board of Directors at a meeting following the Effective Date, you will be awarded six thousand five hundred
(6,500) of the Membership Units, which shall be granted subject to the MEIP Related Documents. You will be required to comply
with the MEIP Related Documents, as amended from time to time.
	 	 	 
	 	 	3. Other Benefits: All other
    compensation and benefits terms (including without limitation, severance terms and post-employment obligations) shall be as
    provided in your Employment Agreement. For purposes of clarity, any changes, modifications, or additions to your compensation
    and benefits terms require the review and approval of Patheon’s Compensation and Human Resources Committee (i.e., cannot
    be approved at the Company level).


 


[SIGNATURE
PAGE FOLLOWS]


 








	 	 	 	 	Page | 2


 











    	 



    	 



    

  


By
executing this Letter, you confirm your decision to accept the amendment to the terms of your Employment Agreement and you agree
that your employment will be governed by the Employment Agreement, as amended by this Letter.


 


	 	Very truly yours,
	 	 
	 	Patheon Pharmaceutical Services Inc.
	 	 
	 	James C. Mullen

    Chief Executive Officer
	 	 















Read,
understood, consented, and agreed as of this ____ day of May, 2014:


 


	SIGNED, SEALED AND DELIVERED	)	 
	                in
    the presence of	)	 
	       	)

                                   )

                                   )

                                   ) 
	      
	Name of Witness:		Stuart Grant


  















	 	 	 	 	Page | 3